iShares Biotechnology ETF
890 hedge funds and large institutions have $5.16B invested in iShares Biotechnology ETF in 2024 Q3 according to their latest regulatory filings, with 81 funds opening new positions, 242 increasing their positions, 317 reducing their positions, and 74 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
24% less repeat investments, than reductions
Existing positions increased: 242 | Existing positions reduced: 317
39% less call options, than puts
Call options by funds: $496M | Put options by funds: $810M
Holders
890
Holding in Top 10
10
Calls
$496M
Puts
$810M
Top Buyers
| 1 | +$78M | |
| 2 | +$65.4M | |
| 3 | +$63.5M | |
| 4 |
BlackRock
New York
|
+$57.3M |
| 5 |
Barclays
London,
United Kingdom
|
+$45.7M |
Top Sellers
| 1 | -$259M | |
| 2 | -$208M | |
| 3 | -$160M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$53.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$31.5M |